021-51111890
购物车（）
sales@molnova.cn
BRD-73954
CAS No. 1440209-96-0
BRD-73954 ( BRD73954 )
产品货号. M11867 CAS No. 1440209-96-0
第一个 HDAC6/8 双抑制剂，IC50 为 36/120 nM。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥125 | 有现货 |
|
| 10MG | ￥168 | 有现货 |
|
| 25MG | ￥332 | 有现货 |
|
| 50MG | ￥498 | 有现货 |
|
| 100MG | ￥712 | 有现货 |
|
| 200MG | ￥1224 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ￥185 | 有现货 |
|
生物学信息
-
产品名称BRD-73954
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述第一个 HDAC6/8 双抑制剂，IC50 为 36/120 nM。
-
产品描述The first HDAC6/8 dual inhibitor with IC50s of 36/120 nM; show no significant inhibition for other HDAC isoforms (IC50>9 uM); robustly increase in α-tubulin acetylation, has no change in the acetylation state of H3 in Hela cells.
-
体外实验BRD73954 (10 μM; 48 h; HeLa cells) inhibits HDAC6 activity via upregulation of Ac-Tubulin. Western Blot Analysis Cell Line:HeLa cells Concentration:10 μM Incubation Time:48 hours Result:Increased inα-tubulin acetylation, no change in the acetylation state of H3 was observed.
-
体内实验——
-
同义词BRD73954
-
通路Cell Cycle/DNA Damage
-
靶点HDAC
-
受体HDAC2|HDAC4|HDAC6|HDAC8
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number1440209-96-0
-
分子量284.3098
-
分子式C16H16N2O3
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 35 mg/mL
-
SMILESC1=CC=C(C=C1)CCNC(=O)C2=CC(=CC=C2)C(=O)NO
-
化学全称1,3-Benzenedicarboxamide, N1-hydroxy-N3-(2-phenylethyl)-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Olson DE, et al. J Med Chem. 2013 Jun 13;56(11):4816-20.
